Browse News
Filter News
Found 10 articles
-
The COVID-19 pandemic that has upended life across the globe has also ignited a reawakening to the value of vaccines, and Hu believes the momentum will carry forward into the new year.
-
Vaxxinity to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/13/2021
The debut of a new U.S. based global biotechnology company, Vaxxinity, will take place at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, at 9:50 a.m. EST.
-
COVAXX Announces Early Design and Testing of New Vaccine Candidate to Address Mutations in SARS-CoV-2
1/8/2021
New York, New York--(Newsfile Corp. - January 8, 2021) - COVAXX, a U.S. company developing a multitope, peptide-based vaccine to fight COVID-19, announced today that the company has initiated preclinical work on a second vaccine candidate to address the latest mutations of the SARS-CoV-2 responsible for COVID-19, and specifically the South African mutation.
-
Aurobindo Pharma and COVAXX Sign an Exclusive Agreement to Develop and Commercialize COVID-19 Vaccine UB-612 for India and UNICEF
12/24/2020
COVAXX's UB-612 is the first multitope, synthetic peptide-based COVID-19 vaccine candidate in clinical trials and it utilizes normal refrigeration (no freezing required) for distribution Agreement leverages Aurobindo's existing development, commercial and manufacturing infrastructure Phase 2/3 clinical trials by COVAXX t
-
COVAXX and Aurobindo Pharma Announce COVID-19 Vaccine Partnership
12/24/2020
Aurobindo Pharma has exclusive rights to develop and commercialize UB-612 in India and to UNICEF and non-exclusive rights in other select emerging markets Expected to support up to 480 million doses of UB-612 for India and other countries Agreement leverages Aurobindo Pharma’s existing development, commercial and manufacturing infrastructure
-
COVAXX Announces $2.8 Billion in Advance Purchase Commitments to Deliver More Than 140 Million Vaccine Doses to Emerging Countries
11/25/2020
COVAXX, a U.S. company developing a multitope peptide-based vaccine to fight COVID-19, announces advanced purchase commitments of more than 140 million doses of its UB-612 vaccine, totaling over $2.8 billion, to deliver vaccines in multiple countries, including Brazil, Ecuador and Peru.
-
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
-
COVAXX Initiates Phase 1 Clinical Trial of COVID-19 Vaccine UB-612 in Taiwan
9/28/2020
- First Healthy Adult Volunteers Safely Dosed with UB-612 - Clinical Trial Currently Enrolling up to 60 Healthy Volunteers - Taiwan's Ministry of Health and Welfare Approves Up to $15M (USD) Grant to Support Phase 1 and 2 of Human Trials - Clinical Trial Expands on Existing International Collaborations with Brazil and U.S.
-
Clinical Catch-Up: September 7-11
9/14/2020
It was a busy week for clinical trial updates. Here’s a look. -
COVAXX Synthetic Multitope Vaccine Selected for Human Trials in Brazil by Dasa, the Largest Diagnostic Company, and Mafra the Leading Private Vaccine Distributor
9/9/2020
Dasa, the largest diagnostic medicine company in Brazil and Latin America, and COVAXX, the subsidiary of United Biomedical Inc, a recognized leader in antibody diagnostics and vaccine development, announced today that they have signed a letter of intent to work together to conduct a large scale human efficacy clinical trial in Brazil to develop a vaccine against COVID-19.